Guillain-Barré Syndrome During Ongoing Zika Virus Transmission - Puerto Rico, January 1-July 31, 2016
- PMID: 27584942
- DOI: 10.15585/mmwr.mm6534e1
Guillain-Barré Syndrome During Ongoing Zika Virus Transmission - Puerto Rico, January 1-July 31, 2016
Abstract
Guillain-Barré syndrome (GBS) is a postinfectious autoimmune disorder characterized by bilateral flaccid limb weakness attributable to peripheral nerve damage (1). Increased GBS incidence has been reported in countries with local transmission of Zika virus, a flavivirus transmitted primarily by certain Aedes species mosquitoes (2). In Puerto Rico, three arthropod-borne viruses (arboviruses) are currently circulating: Zika, dengue, and chikungunya. The first locally acquired Zika virus infection in Puerto Rico was reported in December 2015 (3). In February 2016, the Puerto Rico Department of Health (PRDH), with assistance from CDC, implemented the GBS Passive Surveillance System (GBPSS) to identify new cases of suspected GBS (4). Fifty-six suspected cases of GBS with onset of neurologic signs during January 1-July 31, 2016, were identified. Thirty-four (61%) patients had evidence of Zika virus or flavivirus infection; the median age of these patients was 55 years (range = 21-88 years), and 20 (59%) patients were female. These 34 patients were residents of seven of eight PRDH public health regions. All 34 patients were hospitalized and treated with intravenous immunoglobulin G (IVIg), the standard treatment for GBS; 21 (62%) required intensive care unit admission, including 12 (35%) who required endotracheal intubation and mechanical ventilation. One patient died of septic shock after treatment for GBS. Additionally, 26 cases of neurologic conditions other than GBS were reported through GBPSS, including seven (27%) in patients with evidence of Zika virus or flavivirus infection. Residents of and travelers to Puerto Rico and countries with active Zika virus transmission should follow recommendations for prevention of Zika virus infections.* Persons with signs or symptoms consistent with GBS should promptly seek medical attention. Health care providers in areas with ongoing local transmission seeing patients with neurologic illnesses should consider GBS and report suspected cases to public health authorities.
Similar articles
-
Update: Ongoing Zika Virus Transmission - Puerto Rico, November 1, 2015-July 7, 2016.MMWR Morb Mortal Wkly Rep. 2016 Aug 5;65(30):774-9. doi: 10.15585/mmwr.mm6530e1. MMWR Morb Mortal Wkly Rep. 2016. PMID: 27490087
-
Update: Ongoing Zika Virus Transmission - Puerto Rico, November 1, 2015-April 14, 2016.MMWR Morb Mortal Wkly Rep. 2016 May 6;65(17):451-5. doi: 10.15585/mmwr.mm6517e2. MMWR Morb Mortal Wkly Rep. 2016. PMID: 27149205
-
Local Transmission of Zika Virus--Puerto Rico, November 23, 2015-January 28, 2016.MMWR Morb Mortal Wkly Rep. 2016 Feb 19;65(6):154-8. doi: 10.15585/mmwr.mm6506e2. MMWR Morb Mortal Wkly Rep. 2016. PMID: 26890470
-
Zika virus infection and Guillain-Barré syndrome: a review focused on clinical and electrophysiological subtypes.J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):266-271. doi: 10.1136/jnnp-2016-314310. Epub 2016 Oct 31. J Neurol Neurosurg Psychiatry. 2017. PMID: 27799296 Review.
-
Zika Virus and Patient Blood Management.Anesth Analg. 2017 Jan;124(1):282-289. doi: 10.1213/ANE.0000000000001770. Anesth Analg. 2017. PMID: 27902502 Review.
Cited by
-
In silico screening for potential inhibitors from the phytocompounds of Carica papaya against Zika virus NS5 protein.F1000Res. 2024 Jun 25;12:655. doi: 10.12688/f1000research.134956.2. eCollection 2023. F1000Res. 2024. PMID: 39132582 Free PMC article.
-
Immunological and Safety Considerations When Selecting the Dose Formulation of a Purified Inactivated Zika Virus Vaccine (PIZV).Microorganisms. 2024 Jul 21;12(7):1492. doi: 10.3390/microorganisms12071492. Microorganisms. 2024. PMID: 39065260 Free PMC article.
-
Predicting Efficacy of a Purified Inactivated Zika Virus Vaccine in Flavivirus-Naïve Humans Using an Immunological Correlate of Protection in Non-Human Primates.Microorganisms. 2024 Jun 11;12(6):1177. doi: 10.3390/microorganisms12061177. Microorganisms. 2024. PMID: 38930559 Free PMC article.
-
Neuroinvasion of emerging and re-emerging arboviruses: A scoping review.SAGE Open Med. 2024 May 6;12:20503121241229847. doi: 10.1177/20503121241229847. eCollection 2024. SAGE Open Med. 2024. PMID: 38711470 Free PMC article. Review.
-
Zika Virus-A Reemerging Neurotropic Arbovirus Associated with Adverse Pregnancy Outcomes and Neuropathogenesis.Pathogens. 2024 Feb 15;13(2):177. doi: 10.3390/pathogens13020177. Pathogens. 2024. PMID: 38392915 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
